IL-11Rα antibodies
AssigneesSingapore Health Services Pte Ltd, National University of Singapore
InventorsStuart Alexander Cook, Sebastian Schaefer
Life of this patent
Estimating the term…
Abstract
IL-11Rα antibodies are disclosed. Also disclosed are compositions comprising the IL-11Rα antibodies, and methods using the IL-11Rα antibodies.
Claims15
An antibody or antigen binding fragment, which is capable of binding to IL-11Rα, comprising a light chain variable region sequence and a heavy chain variable region sequence, wherein:
- the light chain variable region sequence comprises the following CDRS:
- (SEQ ID NO:
- 33)
- LC-CDR1:
- QSISNN;
- (SEQ ID NO:
- 34)
- LC-CDR2:
- YAS;
- and
- (SEQ ID NO:
- 35)
- LC-CDR3:
- QQRYSWPLT,
- or a variant comprising 1 amino acid substitution in the sequence QQRYSWPLT (SEQ ID NO:
- 35);
- and
- the heavy chain variable region sequence comprises the following CDRs:
- (SEQ ID NO:
- 60)
- HC-CDR1:
- GYTFTNYW;
- (SEQ ID NO:
- 61)
- HC-CDR2:
- IGPSDSKT;
- and
- (SEQ ID NO:
- 62)
- HC-CDR3:
- ARGDYVLFTY.
A method of treating fibrosis or a disease/disorder characterised by fibrosis, comprising administering an antibody or antigen binding fragment to a subject suffering from fibrosis or a disease/disorder characterised by fibrosis, wherein the antibody or antigen binding fragment is capable of binding to IL-11Rα, and comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
- the light chain variable region sequence comprises the following CDRs:
- (SEQ ID NO:
- 33)
- LC-CDR1:
- QSISNN;
- (SEQ ID NO:
- 34)
- LC-CDR2:
- YAS;
- and
- (SEQ ID NO:
- 35)
- LC-CDR3:
- QQRYSWPLT,
- or a variant comprising 1 amino acid substitution in the sequence QQRYSWPLT (SEQ ID NO:
- 35);
- and
- the heavy chain variable region sequence comprises the following CDRs:
- (SEQ ID NO:
- 60)
- HC-CDR1:
- GYTFTNYW;
- (SEQ ID NO:
- 61)
- HC-CDR2:
- IGPSDSKT;
- and
- (SEQ ID NO:
- 62)
- HC-CDR3:
- ARGDYVLFTY.
Dependencies are inferred from the claim text.